Divalproex sodium in the treatment of adults with bipolar disorder

Expert Rev Neurother. 2004 May;4(3):349-62. doi: 10.1586/14737175.4.3.349.


Divalproex sodium (Depakote, Abbott Laboratories) is an anticonvulsant with well-established efficacy in the treatment of bipolar I disorder, manic or mixed episode. Over the past 10 years, an increased number of studies indicate that divalproex has a broad spectrum of activity in the treatment of bipolar depression and rapid cycling, psychotic symptoms, impulsive aggression and post-traumatic stress disorder. Newer formulations of divalproex, namely the extended-release formulation, are now available. The improved tolerability and convenience of the once-daily extended-release formulation has a significant potential to improve patient compliance and thus, clinical and functional outcomes. The use of divalproex in the treatment of bipolar and other related psychiatric disorders is reviewed.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Adult
  • Bipolar Disorder / complications
  • Bipolar Disorder / drug therapy*
  • Bipolar Disorder / psychology*
  • Diagnosis, Dual (Psychiatry) / trends
  • Humans
  • Valproic Acid / chemistry
  • Valproic Acid / pharmacokinetics
  • Valproic Acid / therapeutic use*


  • Valproic Acid